NCT06421675View on ClinicalTrials.gov

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 28, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Refractory Multiple Myeloma
Interventions
DRUG

Elranatamab injection

Elranatamab (Elrexfio) is a humanized bispecific antibody that targets both BCMA-expressing multiple myeloma (MM) cells and CD3-expressing T cells.

Trial Locations (4)

V5Z 1L3

RECRUITING

Vancouver Cancer Center, Vancouver

L8V 1C3

RECRUITING

Juravinski Cancer Center, Hamilton

N6A 5W9

NOT_YET_RECRUITING

London Health Science Centre - Victoria Hospital, London

K1H 8L6

RECRUITING

Ottawa Hospital, Ottawa

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Ontario Clinical Oncology Group (OCOG)

OTHER